Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

Albert Einstein College of Medicine and Teva Pharmaceuticals, in collaboration with multiple international institutions, ...

After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in ...